Randomized Study of Silq Urinary Catheter

NCT ID: NCT04841226

Last Updated: 2024-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

158 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-28

Study Completion Date

2024-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the ability of the Silq ClearTract™ 100% Silicone 2-Way Foley Catheter to reduce biofilm formation in subjects that require a long-term indwelling Foley catheter when compared to other commercially available urinary catheters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, randomized, multi-center, post-market study in subjects that require a long-term indwelling Foley catheter.

A randomly assigned catheter will be inserted using standard techniques. Non-surgical subjects will rate the level of pain associated with the insertion procedure using the visual analog scale (VAS). A urine sample will be collected immediately after catheter insertion, in order to generate a baseline urinalysis and urine culture.

Follow-up visits will be performed on Day 28, or upon catheter removal, whichever occurs first. The catheter will be removed on Day 28 or earlier if clinically indicated. The removed catheter will be processed and sent to the core laboratory for analysis. Urine will be collected immediately prior to catheter removal in order to conduct urinalysis and urine culture. Subject will rate level of pain associated with the removal procedure using the VAS. The subject will also fill out a questionnaire about their experience with the catheterization immediately after catheter removal. Subjects will then be exited from the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Biofilm Formation UTI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Silq ClearTract™ 100% Silicone 2-Way Foley Catheter

Up to 82 subjects

Group Type ACTIVE_COMPARATOR

Long-term indwelling Foley catheter

Intervention Type DEVICE

Foley Catheter inserted for up to 28-days

Silver-coated Latex 2-Way Foley Catheter

Up to 82 subjects

Group Type ACTIVE_COMPARATOR

Long-term indwelling Foley catheter

Intervention Type DEVICE

Foley Catheter inserted for up to 28-days

Silicone-coated Latex 2-Way Foley catheter

Up to 82 subjects

Group Type ACTIVE_COMPARATOR

Long-term indwelling Foley catheter

Intervention Type DEVICE

Foley Catheter inserted for up to 28-days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Long-term indwelling Foley catheter

Foley Catheter inserted for up to 28-days

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female age ≥ 18 years old;
2. Requiring indwelling 16Fr Foley catheter for at least 7 days;
3. Able and willing to comply with study procedure; and,
4. Able and willing to give informed consent.

Exclusion Criteria

1. Allergy or sensitivity to any catheter materials used in this study;
2. Known urethral stricture which, in the opinion of the investigator, could influence the subject's evaluation of the catheter;
3. Planned Prophylactic use of antibiotics for CAUTI or any other infection beyond day 1 of the study (catheter implantation);
4. Symptomatic UTI being treated with antibiotics (as determined by the study PI, including at least one of the following: fever, chills, headache, burning sensation, burning of urethra or genital area, blood in urine, foul smelling urine and ≥ 10,000 cfu/mL);
5. Any other infection being treated with antibiotics at the time of catheter implantation;
6. Subjects requiring bladder irrigation during the study (an active voiding trial in surgical subjects prior to catheter removal is allowed);
7. Currently enrolled in another interventional clinical trial;
8. Any other condition that, in the opinion of the investigator, precludes study participation or poses a significant hazard in case of study participation; and
9. Females who are pregnant or breastfeeding or who plan to become pregnant during the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Silq Technologies Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Urology Associates of Southern Arizona

Tucson, Arizona, United States

Site Status

Rancho Los Amigos National Rehabilitation Center

Downey, California, United States

Site Status

West Los Angeles VA Medical Center

Los Angeles, California, United States

Site Status

Tri Valley Urology Medical Group

Murrieta, California, United States

Site Status

Providence Saint John's Health Center

Santa Monica, California, United States

Site Status

The Iowa Clinic

West Des Moines, Iowa, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Evergreen Health

Kirkland, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STC-001/F

Identifier Type: -

Identifier Source: org_study_id